LABORATORY RESEARCH USE ONLY. NOT INTENDED FOR CONSUMPTION.

GLP-2 — Published Research

Reviewed by: Elizabeth D.| Last updated: abril 30, 2026|For laboratory reference only

How to read this GLP-2 research page

Use this page as a literature and documentation map for GLP-2 naming, receptor-model terminology, and batch verification links. It is designed to connect the product page, COA directory, quality standards, and related GLP research pages.

For comparison across Panda’s GLP catalog, review molecular identity, naming conventions, product documentation, and COA status rather than clinical or consumer-use outcomes.

This page does not provide consumer-use, application, procedural, preparation, clinical-use, outcome, or non-research-use guidance.

← Back to GLP-2 product page

Ver reportes de laboratorio · Calidad y pruebas · Preguntas frecuentes

Biblioteca de investigación

Published research on this compound — for educational purposes only

Mechanism as an imbalanced dual agonist

GLP-2 is characterized as an “imbalanced” dual agonist because it displays full agonism at the GIP receptor but biased agonism at the GLP-1 receptor. At the GLP-1R, GLP-2 preferentially activates Gαs-mediated cAMP signaling while exhibiting reduced β-arrestin recruitment compared to native GLP-1. This biased signaling profile results in less receptor internalization and potentially sustained receptor surface availability. The compound’s C-20 fatty diacid moiety enables albumin binding and alters its stability profile in preclinical characterization. For laboratory research use only.

Willard FS, et al. JCI Insight. 2020;5(17):e140532. JCI Insight

GLP-1R signaling vs selective GLP-1 agonists

Unlike selective GLP-1 receptor agonists such as GLP-1 S, GLP-2 demonstrates biased agonism at GLP-1R characterized by reduced β-arrestin-1 recruitment. Selective GLP-1 agonists activate both cAMP and β-arrestin pathways with relatively balanced efficacy, leading to robust receptor internalization. GLP-2’s biased profile — favoring cAMP over β-arrestin — may alter receptor trafficking dynamics. The simultaneous engagement of GIP receptors with full agonism distinguishes GLP-2’s pharmacological signature from mono-agonist compounds. For laboratory research use only.

Min Q, et al. Proc Natl Acad Sci USA. 2022;119(34):e2116506119. PNAS

cAMP vs β-arrestin receptor pharmacology

In cell-based assays, GLP-2 activates GIP receptor-mediated cAMP accumulation with potency comparable to native GIP. At the GLP-1 receptor, GLP-2 generates cAMP with approximately 5-fold lower potency than native GLP-1, but displays markedly reduced (>100-fold) β-arrestin-1 and β-arrestin-2 recruitment. This dissociation between G-protein signaling and arrestin recruitment defines GLP-2 as a G-protein-biased agonist at GLP-1R. For laboratory research use only.

Willard FS, et al. JCI Insight. 2020;5(17):e140532. JCI Insight

Structural basis for dual receptor engagement

GLP-2 is a 39-amino acid linear peptide based on the native GIP sequence with modifications enabling GLP-1R cross-reactivity. Key structural features include an α-aminoisobutyric acid (Aib) substitution at position 2 conferring DPP-4 resistance, and a C-20 fatty diacid moiety conjugated via a linker at lysine-20 enabling non-covalent albumin binding. The exendin-4-derived C-terminal extension (positions 35-39) contributes to GLP-1R engagement. For laboratory research use only.

Min Q, et al. Proc Natl Acad Sci USA. 2022;119(34):e2116506119. PNAS

Continue reviewing GLP-2

Use the research references above alongside Panda’s batch documentation and catalog specifications.

Disclaimer: All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use only. This page is provided for research-reference and documentation review only.

Reviewed by

Elizabeth D.

Research content reviewer focused on peptide literature review, documentation quality, and reference completeness.

Editorial Review

Reviewed by Elizabeth D. y James S. — Panda Peptides Research Team.

Last reviewed: June 2026.

This content summarizes published laboratory literature for research-reference purposes only. Products referenced by Panda Peptides are sold strictly for controlled laboratory, analytical, or reference use and are not consumer products.